RETICAD helps identify patients with retinal diseases who may benefit from treatment
This patent-protected software measures critical hallmarks of retinal diseases caused by diabetes and aging, including vascular leakage and non-perfusion.
By doing so, it allows the identification of patients who may benefit from interventions that target these disease hallmarks.
RETICAD's measures of leakage and perfusion
Vascular leakage before treatment
Tissue perfusion before treatment
Reduced vascular leakage after treatment
0.16
Leakage rate
0
18
Perfusion rate
0
Improved tissue perfusion after treatment
GenFA makes detection of vascular leakage and non-perfusion highly accessible
This patent-pending software enables accessible visualization of vascular leakage and non-perfusion without the need for dye injection.
PUBLICATIONS
-
Link Between Baseline Peripheral Vascular Leakage and Treatment Response in Patients with Central Retinal Vein Occlusion: A Pilot Study.
Clinical Ophthalmology. 2026.
-
Retinal Vessel Dysfunction in Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy.
Neurology Open Access. 2026.
-
Quantitative Fluorescein Angiography Biomarkers in Diabetic Macular Edema.
Retina. 2025.
-
Mechanisms of blood-retinal barrier disruption related to intraocular inflammation and malignancy.
Prog Retin Eye Res. 2024
-
Association of Intravenous Fluorescein Angiography and Adaptive Optics Imaging in Diabetic Retinopathy.
Retina. 2024.
-
Artificial intelligence-based extraction of quantitative ultra-widefield fluorescein angiography parameters in retinal vein occlusion.
Can J Ophthalmol. 2024
-
Artificial Intelligence-Enhanced Analysis of Retinal Vasculature in Age-Related Macular Degeneration.
Retina. 2024.
-
Angiographic evidence of proliferative retinopathy predicts neuropsychiatric morbidity in diabetic patients.
Psychoneuroendocrinology. 2016.
-
Novel fluorescein angiography-based computer-aided algorithm for assessment of retinal vessel permeability.
PLoS One. 2013.